7,8 Correct microscopic recognition of babesiosis is a challenge in non-endemic regions foremost due to the rarity of the disease. Interestingly, serology is also an imperfect diagnostic tool.

Delayed antibody response and a low cross reactivity between different Babesia spp. may lead to negative serologic results despite active Babesia spp. infection as observed in our case. PCR detection of Babesia-specific DNA in patients’ blood may therefore serve as diagnostic gold standard providing at the same time the direct proof of infection and enabling species determination by further sequence analysis. B. divergens is the most widely distributed species in Europe and leads to clinical disease almost exclusively Bcl-2 cleavage in splenectomized patients. JAK2 inhibitors clinical trials Consistently, to date only one clinical case of Babesia spp. infection has been reported from Austria.5 However, New World babesiosis—most commonly caused by B. microti—often occurs in otherwise healthy individuals and may lead to potentially life-threatening complications. One of the underlying reasons for the incorrect diagnosis of falciparum malaria was the selective

reporting of potentially hazardous geographic exposure by the patient by exclusively reporting the travel to Latin America and not mentioning the subsequent and four times longer residence in Massachusetts, USA.9 This fact may remind physicians once again of actively pursuing the patient’s

history with utmost diligence—even if a diagnosis may seem likely at first sight. The authors wish to thank Iveta Häfeli, Medical Parasitology, Institute of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, for excellent technical assistance. The authors acknowledge Prof. Schwarzinger’s help in photographic documentation of blood smears. The authors state that they have no conflicts of interest. “
“Figure 1 was inadvertently replaced by Figure 2, resulting in Figure 2 appearing twice in the article. Below is the correct Figure 1 and its legend. “
“Background. Because bacterial pathogens are the primary cause Ergoloid of travelers’ diarrhea (TD), antibiotic prophylaxis is effective in TD prevention. This study assessed the efficacy and safety of the nonsystemic antibiotic rifaximin in preventing TD in US travelers to Mexico. Methods. Healthy adult students traveling to Mexico received rifaximin 600 mg/d or placebo for 14 days and were followed for 7 days post-treatment. Stool pattern and gastrointestinal symptoms were recorded in daily diary entries. The primary end point was prevention of TD during 14 days of treatment measured by time to first unformed stool. Results. A total of 210 individuals received rifaximin (n = 106) or placebo (n = 104) and were included in the safety population. Median age was 21 years (range, 18–75 y), and the majority of participants were female (65%).